Search | IOVS | ARVO Journals

View

Showing 1 – 20 of 28

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

OSA Fall Vision Meeting Abstract June 2017

Recording fixational eye movements with a new AOSLO: simulation, measurement and evaluation

Laura K. Young; Anna K. Hauperich; Timothy J. Morris; Christopher D. Saunter; Hannah E. Smithson

Journal of Vision. 2017; 17(7):34. doi: https://doi.org/10.1167/17.7.34

ARVO Annual Meeting Abstract April 2014

Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients

Tuyen Ong; Catherine Allaire; Timothy W Morris; Baldo Sforzolini

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5790. doi:

ARVO Annual Meeting Abstract April 2014

Simultaneous Determination of the Rate of Disinfection and Peroxide Neutralization of a Novel Hydrogen Peroxide Disinfecting System

Deborah McGrath; Kimberly A Millard; Damien Cordero; Timothy W Morris

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6052. doi:

ARVO Annual Meeting Abstract April 2014

Antibiotic Resistance Profile of Ocular Pathogens - An Update from the 2013 US ARMOR Surveillance Study

Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Deborah C Draghi; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6281. doi:

ARVO Annual Meeting Abstract April 2014

Influence of Buffering Systems on Acanthamoeba Encystment Following Prolonged Storage with Experimental Formulations and a Novel Hydrogen Peroxide-based Disinfecting Solution

Shawn C Lynch; Christopher Kovacs; Kimberly A Millard; Suzanne F Groemminger; Timothy W Morris

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4645. doi:

ARVO Annual Meeting Abstract April 2014

In vitro Antibiotic Susceptibility Profile of Ocular Pathogens - Results from the First ARMOR Canada Surveillance Study

Joseph M Blondeau; Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2840. doi:

ARVO Annual Meeting Abstract June 2013

Genomics of the Conjunctival Pathogen Streptococcus pneumoniae

Michael Valentino; Wolfgang Haas; Christine Sanfilippo; Jason Rosch; Elaine Tuomanen; Timothy Morris; Michael Gilmore

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5222. doi:

ARVO Annual Meeting Abstract June 2013

Prevalence and characteristics of MRSA from clinical conjunctivitis trials versus ocular surveillance studies

Timothy Morris; Christine Sanfilippo; Christine Hesje; Matthew MacGilvray; Wolfgang Haas

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2886. doi:

ARVO Annual Meeting Abstract June 2013

Antibiotic Resistance Surveillance of Ocular Pathogens - four years of ARMOR Study Results

Wolfgang Haas; Jennifer Deane; Timothy Morris; Daniel Sahm

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2904. doi:

ARVO Annual Meeting Abstract June 2013

Novel Minimum Inhibitory Concentration (MIC) Assay to Measure the Effectiveness of Antimicrobial Treatments Against Acanthamoeba Trophozoites and Cysts

Christopher Kovacs; Shawn Lynch; Joseph Carr; Christine Sanfilippo; Wolfgang Haas; Jenilee Kilbury; Kimberly Millard; Timothy Morris

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2921. doi:

ARVO Annual Meeting Abstract June 2013

A Plaque Method for Direct and Sensitive Enumeration of Surviving Acanthamoeba During Biocidal Efficacy and Regimen Testing of Contact Lens Disinfection Solutions

Shawn Lynch; Joseph Carr; Christopher Kovacs; Matthew Dehmler; Todd Bassage; Wolfgang Haas; Timothy Morris

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5449. doi:

ARVO Annual Meeting Abstract June 2013

Atypical Pathogens Observed in Recent Clinical Studies of Bacterial Conjunctivitis

Lynne Gearinger; Christine Sanfilippo; Lening Zhang; Wolfgang Haas; Timothy Comstock; Timothy Morris

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5450. doi:

ARVO Annual Meeting Abstract March 2012

Strain ST448 Causes the Majority of Pneumococcal Conjunctivitis Cases

Christine M. Sanfilippo; Wolfgang Haas; Christine K. Hesje; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):83. doi:

ARVO Annual Meeting Abstract March 2012

Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against Less Common Conjunctivitis Pathogens of Ophthalmic Interest

Timothy L. Comstock; Heleen H. DeCory; Lynne S. Gearinger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4007. doi:

ARVO Annual Meeting Abstract March 2012

Clinical efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE

Heleen H. DeCory; Timothy L. Comstock; Lynne S. Gearinger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1862. doi:

ARVO Annual Meeting Abstract March 2012

Evaluation of Acanthamoeba Encystment for a Novel One-Step Hydrogen Peroxide Disinfecting Solution and Comparator Peroxide Disinfecting Solutions

Shawn C. Lynch; Christopher J. Kovacs; Joseph G. Carr; Matthew A. Dehmler; Kimberly A. Millard; Michael J. Schoene; Suzanne F. Groemminger; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6080. doi:

ARVO Annual Meeting Abstract March 2012

Regimen Testing of a Novel One-Step Hydrogen Peroxide Disinfecting Solution and Comparators with Soft Contact Lenses and Ocular Clinical Isolates

Jessica M. Burger; Todd H. Bassage; Arthur J. Principe; Deborah McGrath; Patricia A. Walsh; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6083. doi:

ARVO Annual Meeting Abstract March 2012

Pharmacodynamic Analysis of Hydrogen Peroxide Solution Disinfection Efficacy in One-Step Peroxide Neutralizing Lens Cases

Timothy W. Morris; Damien W. Cordero; Deborah McGrath; Suzanne F. Groemminger; Kimberly A. Millard

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6084. doi:

ARVO Annual Meeting Abstract March 2012

Antibiotic Resistance Profile of Ocular Pathogens - An Update from the ARMOR 2011 Surveillance Study

Wolfgang Haas; Jennifer Deane; Timothy W. Morris; Daniel F. Sahm

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6195. doi:

ARVO Annual Meeting Abstract March 2012

Microbiological Eradication Rates with BID or TID Dosing of Besifloxacin Ophthalmic Suspension, 0.6% in Bacterial Conjunctivitis Clinical Trials from 2004 - 2010

Kirk Bateman; Timothy L. Comstock; Lynne S. Gearinger; Christine K. Hesje; Christine M. Sanfilippo; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6198. doi:

1 2

Next 20 Results »

Advertisement